Search Main Menu Main Content
  • Change contrast :
Retour à l'accueil du site de la HAS
logo HAS
icone
  • HAS profile
    • Mission
    • Organisational Structure
    • Ethics, transparency and management of conflicts of interest
  • International relations and projects
  • Publications
  1. root
  2. ANAGRELIDE AOP (anagrélide)
  • icone plus
  • My account

    • Email alert Subscription
    • Newsletter Subscription
    • My search
    Refresh
    Please fill in your email address to retrieve your email alerts subscriptions.
    New subscription
    Please fill in your email address to retrieve your newsletter subscriptions.

    You do not have a saved search

    Mon Compte
  • No element in selection

    Favoris
  • Établissements de santé
  • Contact Abonnez-vous aux actualités
Listen Listen
Add to my selection
  • History
  • Technical informations
Share
Share on
Facebook share - facebook.com - new window
Tweeter share - Partager sur Twitter - twitter.com - new window
LinkedIn share - linkedin.com - new window
Print

ANAGRELIDE AOP (anagrélide)

Medicine - Posted on Jan 06 2020
Active substance (DCI)
  • anagrélide
history (1)
  • 12/11/19

    ANAGRELIDE AOP (anagrélide)

    Key points Unfavourable opinion for reimbursement for the reduction of elevated platelet counts and the associated clinical ...
    icône flèche
Technical information
ATC code
  • L01XX35
Manufacturer
AOP ORPHAN PHARMACEUTICALS AG
Presentation

ANAGRELIDE AOP 0,5 mg, gélule
B/100 - Code CIP : 34009 301482 2 8

All our publications
    Blood and lymphatic diseases - miscellaneous Bone marrow diseases Drug therapy

Follow us :

  • Twitter (nouvelle fenêtre)
  • Facebook (nouvelle fenêtre)
  • Youtube (nouvelle fenêtre)
  • LinkedIn (nouvelle fenêtre)
Haute Autorité de Santé
Advancing quality in the fields of health and social care services
  • Eunetha.eu
  • Pasq.eu
  • All our publications by topic and type
  • Opinions on medicines
  • Opinions on medical devices
  • INAHTA briefs
  • Français
  • English
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
REjHNWfS4MEqySSq